UNSPSC 51122801: Almokalant

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C18H28N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) I9NG89L275, chemically known as benzonitrile, 4-(3-(ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxypropoxy)- but more generally known as almokalant, which bears US NIH Compound Identifier 3033962. European Medicines Agency schedules Almokalant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05349MIG.

UNSPSC 51122801 Almokalant, a Commodity code, covers emergency medications and pharmaceutical preparations that state and local governments procure for emergency medical services, public health programs, and institutional healthcare operations. Recent solicitations show state and local buyers purchasing specific pharmaceutical line items—epinephrine, adenosine, labetalol, diltiazem, and other advanced life support medications—in discrete unit quantities with firm pricing, expedited delivery windows, and expiration-date guarantees. The code encompasses both direct procurement of finished pharmaceuticals by individual municipalities and regional cooperative-purchasing arrangements that aggregate demand across multiple jurisdictions and state agencies.

Issuing bodies range from city fire and rescue departments to state health agencies and multistate cooperative purchasing alliances. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB 26P00188, due April 8, 2026, estimated value $40,000) for Tampa Fire Rescue through sealed bid with SLBE sheltered-market designation and a 5 percent bid discount. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed to participating state and local facilities in Minnesota and Oregon through three authorized wholesalers, with two-year contract terms and performance penalties for reporting or onboarding failures. Recent activity spans Florida, Texas, and the Upper Midwest, with demand driven by emergency response needs, institutional inventory management, and state-level efforts to optimize pharmacy procurement across multiple jurisdictions.